SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis

Published:2018-07-26 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Corvol Harriet,Mésinèle Julie,Douksieh Isman-Hassan,Strug Lisa J.,Boëlle Pierre-Yves,Guillot Loïc

Funder

Agence Nationale de la Recherche

Cystic Fibrosis Foundation

Institut National de la Santé et de la Recherche Médicale

Assistance publique-Hôpitaux de Paris

Association Vaincre la Mucoviscidose

GIS-Institut des Maladies Rares

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines.;Avella;J. Cell. Physiol.,2011

2. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.;Bertrand;Am. J. Physiol. Lung Cell. Mol. Physiol.,2017

3. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.;Bertrand;J. Gen. Physiol.,2009

4. Genetic modifiers of cystic fibrosis-related diabetes.;Blackman;Diabetes Metab. Res. Rev.,2013

5. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.;Chang;J. Biol. Chem.,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation;Clinica Chimica Acta;2024-07

2. The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR Mutations;2024-01-04

3. Research Progress of the Relationship between Phenotypic Variability and Modifier Genes in Cystic Fibrosis;Advances in Clinical Medicine;2024

4. Transgenic ferret models define pulmonary ionocyte diversity and function;Nature;2023-09-20

5. The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?;Expert Opinion on Pharmacotherapy;2023-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3